Progression to type 2 diabetes, healthcare utilization, and cost among pre-diabetic patients with or without comorbid hypertension

Current Medical Research and Opinion

Volumn 27, Issue 4, 2011, Pages 809-819

  Francis, Bruce H ^a   Song, Xue ^b   Andrews, L M ^a   Purkayastha, Das ^a   Princic, Nicole ^b   Sedgley, Robert ^b   Rudolph, Amy E ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b THOMSON REUTERS   (United States)

Author keywords

Healthcare costs; Healthcare utilization; Hypertension; Pre diabetes; Type 2 diabetes

Indexed keywords

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE COURSE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REIMBURSEMENT; RISK FACTOR; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MODELS, STATISTICAL; PREDIABETIC STATE;

EID: 79952660194     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.554806     Document Type: Article

References (29)

1. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 2006;24:1263-8
2. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007;30:753-9 (Pubitemid 46354366)
3. Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-40
4. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403 (Pubitemid 34437694)
5. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008.
6. Haffner SM, Mykkanen L, Festa A, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000;101:975-80 (Pubitemid 30131698)
7. Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893-8 (Pubitemid 20173164)
8. Nichols GA and Moler EJ. Diabetes incidence for all possible combinations of metabolic syndrome components. Diabetes Res Clin Pract 2010;90:115-21
9. Zhang Y, Dall TM, Chen Y, et al. Medical cost associated with prediabetes. Popul Health Manag 2009;12:157-63
10. Dall TM, Zhang Y, Chen YJ, et al. The economic burden of diabetes. Health Aff (Millwood) 2010;29:297-303
11. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004;43:963-9 (Pubitemid 38579899)
12. Lindstrom J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673-9 (Pubitemid 46048554)
13. Chiasson JL. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr Pract 2006;12(S1):25-30
14. McMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477-90
15. Bertram MY, Lim SS, Barendregt JJ, et al. Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care. Diabetologia 2010;53:875-81
16. Herman WH, Hoerger TJ, Brandle M, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142:323-32 (Pubitemid 40293405)
17. Li R, Zhang P, Barker LE, et al. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care 2010;33:1872-94
18. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105
19. Hernan WH, Brandle M, Zhang P, et al. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care 2003;26:36-47 (Pubitemid 36928992)
20. Zhang C, Knudson JD, Setty S. et al. Coronary arteriolar vasoconstriction to angiotensin II is augmented in prediabetic metabolic syndrome via activation of AT1 receptors. Am J Physiol Heart Circ Physiol. 2005;288:H2154-H2162 (Pubitemid 40604100)
21. Guyton AC. Textbook of Physiology. 10th edition. WB Saunders Company, 2000 195-209
22. Carmilla M, Licht M, Vreeberg SA, et al. Increased sympathetic and decreased parasympathetic activity rather than changes in hypothalamic- pituitary-adrenal axis activity is associated with metabolic abnormalities. J Clin Endocrinol Metab. 2010;95:2458-66
23. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin- convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53
24. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003 (Pubitemid 34286536)
25. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31 (Pubitemid 38781102)
26. Yusuf S, Ostergren JB, Gerstein HC, et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005;112:48-53 (Pubitemid 40962568)
27. Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551-62 (Pubitemid 44550032)
28. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care 2011;34(S1):S11-61
29. Garber AJ, Handelsman Y, Einhorn D, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract 2008;14:933-46